The FDA Reboot of Antibiotic Development

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2013 Jul 31

PMID 23896479

Citations 60

Authors

David M Shlaes

Dan Sahm

Carol Opiela

Brad Spellberg

Affiliations

Soon will be listed here.

Citing Articles

Beyond Antibiotics: What the Future Holds.

Benyamini P Antibiotics (Basel). 2024; 13(10).

PMID: 39452186 PMC: 11504868. DOI: 10.3390/antibiotics13100919.

Antibiotics: From Mechanism of Action to Resistance and Beyond.

Saikia S, Chetia P Indian J Microbiol. 2024; 64(3):821-845.

PMID: 39282166 PMC: 11399512. DOI: 10.1007/s12088-024-01285-8.

The Natural History of Antibiotic-Treated Lower Limb Cellulitis: Analysis of Data Extracted From a Multicenter Clinical Trial.

Williams O, Hamilton F, Brindle R Open Forum Infect Dis. 2023; 10(10):ofad488.

PMID: 37849504 PMC: 10578506. DOI: 10.1093/ofid/ofad488.

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs.

Mitra-Majumdar M, Powers 3rd J, Brown B, Kesselheim A BMJ Med. 2023; 1(1):e000227.

PMID: 36936591 PMC: 9978751. DOI: 10.1136/bmjmed-2022-000227.

Development of a Bispecific Antibody Targeting Clinical Isolates of Acinetobacter baumannii.

Nielsen T, Yan J, Slarve M, Li R, Junge J, Luna B J Infect Dis. 2023; 227(9):1042-1049.

PMID: 36617220 PMC: 10319980. DOI: 10.1093/infdis/jiac499.

References

Spellberg B . Acute bacterial skin and skin structure infection trials: the bad is the enemy of the good. Clin Infect Dis. 2011; 53(12):1308-9. DOI: 10.1093/cid/cir741. View

Cooper M, Shlaes D . Fix the antibiotics pipeline. Nature. 2011; 472(7341):32. DOI: 10.1038/472032a. View

Shlaes D, Moellering R . Telithromycin and the FDA: implications for the future. Lancet Infect Dis. 2008; 8(2):83-5. DOI: 10.1016/S1473-3099(08)70002-1. View

. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013; 62(9):165-70. PMC: 4604788. View

Projan S, Shlaes D . Antibacterial drug discovery: is it all downhill from here?. Clin Microbiol Infect. 2004; 10 Suppl 4:18-22. DOI: 10.1111/j.1465-0691.2004.1006.x. View

Spellberg B, Bartlett J, Gilbert D . The future of antibiotics and resistance. N Engl J Med. 2013; 368(4):299-302. PMC: 3617123. DOI: 10.1056/NEJMp1215093. View

Hidron A, Edwards J, Patel J, Horan T, Sievert D, Pollock D . NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008; 29(11):996-1011. DOI: 10.1086/591861. View

Rex J, Eisenstein B, Alder J, Goldberger M, Meyer R, Dane A . A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis. 2013; 13(3):269-75. DOI: 10.1016/S1473-3099(12)70293-1. View

Spellberg B, Sharma P, Rex J . The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov. 2012; 11(2):168. PMC: 3883457. DOI: 10.1038/nrd3560-c1. View

10.

Echols R . A long and winding road; evolution of antimicrobial drug development - crisis management. Expert Rev Anti Infect Ther. 2012; 10(11):1311-9. DOI: 10.1586/eri.12.131. View

11.

. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis. 2012; 55(8):1031-46. PMC: 3657525. DOI: 10.1093/cid/cis688. View

12.

Shlaes D, Moellering Jr R . The United States Food and Drug Administration and the end of antibiotics. Clin Infect Dis. 2002; 34(3):420-2. DOI: 10.1086/338976. View

13.

Temple R, Ellenberg S . Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000; 133(6):455-63. DOI: 10.7326/0003-4819-133-6-200009190-00014. View

14.

Snodgrass W, Anderson T . Prontosil in Erysipelas. Br Med J. 2010; 2(3993):101-4. PMC: 2086972. DOI: 10.1136/bmj.2.3993.101. View

15.

Snodgrass W, Anderson T . Sulphanilamide in the Treatment of Erysipelas. Br Med J. 2010; 2(4014):1156-9. PMC: 2087874. DOI: 10.1136/bmj.2.4014.1156. View